News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
288,481 Results
Type
Article (15303)
Company Profile (301)
Press Release (272871)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (81637)
Career Advice (173)
Deals (13694)
Drug Delivery (40)
Drug Development (51164)
Employer Resources (31)
FDA (6004)
Job Trends (5348)
News (148031)
Policy (10349)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (969)
Accelerated approval (20)
Adcomms (14)
Allergies (82)
Alliances (22228)
ALS (124)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6203)
Artificial intelligence (259)
Autoimmune disease (110)
Automation (9)
Bankruptcy (109)
Best Places to Work (4688)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (349)
Cancer (3143)
Cardiovascular disease (237)
Career advice (157)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (565)
Cervical cancer (14)
Clinical research (44057)
Collaboration (1151)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1138)
CRISPR (86)
C-suite (552)
Cystic fibrosis (122)
Data (4340)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1413)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (189)
Drug pricing (50)
Drug shortages (4)
Duchenne muscular dystrophy (214)
Earnings (32304)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (52427)
Executive appointments (626)
FDA (7768)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (987)
Gene editing (182)
Generative AI (21)
Gene therapy (488)
GLP-1 (505)
Government (1193)
Grass and pollen (4)
Guidances (170)
Healthcare (6717)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (191)
Immuno-oncology (39)
Indications (66)
Infectious disease (1243)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (19)
IPO (7459)
IRA (12)
Job creations (920)
Job search strategy (139)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (245)
Leadership (9)
Legal (1428)
Liver cancer (42)
Longevity (11)
Lung cancer (422)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (130)
Medical device (2853)
Medtech (2864)
Mergers & acquisitions (6859)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1953)
Neurotech (1)
NextGen: Class of 2026 (2123)
Non-profit (905)
Now hiring (31)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (104)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (304)
Patient recruitment (332)
Peanut (43)
People (27201)
Pharmaceutical (45)
Pharmacy benefit managers (6)
Phase 1 (15549)
Phase 2 (20445)
Phase 3 (12989)
Pipeline (3280)
Policy (91)
Postmarket research (869)
Preclinical (6592)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (660)
Real estate (1521)
Recruiting (12)
Regulatory (10120)
Reports (19)
Research institute (997)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (123)
Series A (184)
Series B (136)
Service/supplier (1)
Sickle cell disease (79)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (16)
Startups (2023)
State (1)
Stomach cancer (5)
Supply chain (34)
Tariffs (18)
The Weekly (62)
Vaccines (339)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (13)
Last 7 days (349)
Last 30 days (1137)
Last 365 days (17947)
2026 (1675)
2025 (18236)
2024 (20716)
2023 (22715)
2022 (27244)
2021 (28490)
2020 (23916)
2019 (16786)
2018 (12165)
2017 (14079)
2016 (12167)
2015 (14804)
2014 (10761)
2013 (7793)
2012 (7835)
2011 (7924)
2010 (7702)
Location
Africa (161)
Alabama (65)
Alaska (2)
Arizona (77)
Arkansas (5)
Asia (18553)
Australia (3182)
California (7104)
Canada (1851)
China (773)
Colorado (247)
Connecticut (254)
Delaware (242)
Europe (40024)
Florida (910)
Georgia (210)
Hawaii (2)
Idaho (18)
Illinois (398)
India (35)
Indiana (163)
Iowa (8)
Japan (226)
Kansas (82)
Kentucky (10)
Louisiana (7)
Maine (11)
Maryland (744)
Massachusetts (5618)
Michigan (111)
Minnesota (257)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1659)
New Mexico (15)
New York (1778)
North Carolina (845)
North Dakota (6)
Northern California (3485)
Ohio (182)
Oklahoma (11)
Oregon (24)
Pennsylvania (1293)
Puerto Rico (9)
Rhode Island (26)
South America (227)
South Carolina (11)
Southern California (2820)
Tennessee (40)
Texas (908)
United States (23528)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
288,481 Results for "aer therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aer Therapeutics to Participate at Cantor Global Healthcare Conference 2025
August 28, 2025
·
1 min read
Bio NC
Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference
Aerami Therapeutics announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society 2024 International Conference being held May 17-22, 2024, in San Diego, California.
May 20, 2024
·
6 min read
Press Releases
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
January 8, 2025
·
6 min read
Bio NC
Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
Aerami Therapeutics today announced that pharmacokinetic modeling data for AER-901, a proprietary liquid formulation of imatinib for inhalation that is administered by a breath-activated, high-performance, handheld, smart nebulizer, will be presented at the upcoming CHEST 2023 conference.
October 5, 2023
·
6 min read
Business
Aer Therapeutics Raises $36M for Novel Approach to COPD
Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.
April 14, 2023
·
3 min read
·
Kate Goodwin
Drug Development
Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress
Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, today announced the presentation of results from the randomized double-blind, placebo-controlled Phase 1 clinical trial (NCT04903730) of AER-901 at the 2023 European Respiratory Society (ERS) International Congress.
September 12, 2023
·
7 min read
Drug Development
Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension
Aerami Therapeutics (“Aerami”) today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
May 24, 2023
·
5 min read
Drug Development
Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension
Aerami Therapeutics announced new additions to its management team as the company prepares for the imminent initiation of the planned “uniPHied” Phase 2 trial of AER-901, in pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
June 1, 2023
·
6 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Bio NC
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference
Aerami Therapeutics (“Aerami”) today announced that non-clinical pharmacokinetic data and details of the completed AER-901 Phase 1 trial in healthy volunteers will be presented at the 2023 American Thoracic Society (ATS) International Conference, being held at the Walter E. Washington Convention Center in Washington, D.C. from May 19-24, 2023.
May 11, 2023
·
5 min read
1 of 28,849
Next